Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intraluminal Metronidazole for H. Pylori Infection
NCT03524833Phase 4Completed
- Sponsor
- Mackay Memorial Hospital
- Start
- May 2018
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of metronidazole in Helicobacter pylori infection (2 arms), sponsored by Mackay Memorial Hospital. Primary endpoint: Eradication rate in the intraluminal therapy at 6 weeks. Started May 2018; status: completed.
02
Drugs
metronidazole
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on NCT03524833.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03524833.